Moving CAR-T Into Earlier Lines of Myeloma Treatment

(MedPage Today) -- Updated results from the CARTITUDE-1 trial showed that 33% of patients with heavily pretreated relapsed/refractory multiple myeloma who received ciltacabtagene autoleucel (cilta-cel; Carvykti) were alive and progression free...